Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Gresham

Psychiatry Livonia, MI Medical Doctor

NPI 1700014511 CMS profile 1009488

19986 Sunbury St, Livonia, MI 48152

Open in the dashboard

General payments

$13,885

969 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Gresham of Livonia, MI is reported in the CMS Open Payments database as having received $13,885 across 969 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,936 112
2024 General $2,113 117
2023 General $2,321 163
2022 General $2,368 183
2021 General $2,193 183
2020 General $1,640 111
2019 General $1,313 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Gresham
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Patrick Gresham were reported at $1,936. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Patrick Gresham Psychiatry median Middle half National median
2019 $1,313 $184 $59–$605 $163
2020 $1,640 $119 $36–$372 $114
2021 $2,193 $143 $43–$576 $132
2022 $2,368 $153 $50–$590 $149
2023 $2,321 $170 $56–$651 $160
2024 $2,113 $179 $57–$673 $164
2025 $1,936 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $1,532 71 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,215 91 payments
  3. Lundbeck LLC $1,196 84 payments
  4. Otsuka America Pharmaceutical, Inc. $1,172 70 payments
  5. Tris Pharma Inc $1,106 98 payments
  6. Supernus Pharmaceuticals, Inc. $1,089 185 payments
  7. Vanda Pharmaceuticals Inc. $933 41 payments
  8. AbbVie, Inc. $925 62 payments
  9. Janssen Pharmaceuticals, Inc $897 48 payments
  10. Neurocrine Biosciences, Inc. $602 31 payments
  11. Other $3,219 188 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,831 967 payments
  2. Education $54 2 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA $1,149 54 payments
  2. REXULTI Psychiatry $973 58 payments
  3. TRINTELLIX $929 54 payments
  4. SPRAVATO $897 48 payments
  5. REXULTI Psychiatry $889 60 payments
  6. QELBREE $873 154 payments
  7. HETLIOZ $835 36 payments
  8. VRAYLAR $826 58 payments
  9. Dyanavel XR $583 49 payments
  10. Azstarys $500 30 payments
  11. Other $7,319 454 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

747

Median for Psychiatry & Neurology: 100

Drug cost

$28,492

Median for Psychiatry & Neurology: $2,986

Branded share of claims

20.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 12 $16,947
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 44 $2,145
Fluoxetine Hcl Generic 37 $1,061
Sertraline Hcl Generic 64 $907
Escitalopram Oxalate Generic 52 $888
Trazodone Hcl Generic 53 $874
Bupropion Hcl Generic 20 $695
Bupropion Xl Bupropion Hcl Brand 25 $528
Aripiprazole Generic 38 $527
Buspirone Hcl Generic 27 $494

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$290 — —
CAPLYTA
$255 — —
VRAYLAR
$227 12 —
SPRAVATO
$188 — —
Dyanavel XR
$179 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

969 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record